STOCK TITAN

Inspira Technologies Oxy Bhn Ltd - IINN STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.

Overview

Inspira Technologies Oxy BHN Ltd (IINN) is a specialty medical device company committed to transforming the landscape of respiratory care. With a focus on life support and respiratory treatment, the company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART) that provides a non-invasive alternative to traditional mechanical ventilation. The technology is designed to elevate oxygen saturation and reduce carbon dioxide levels in patients, addressing a critical need in the management of acute respiratory failure.

Core Technology and Innovation

The hallmark of Inspira Technologies is its pioneering approach to respiratory support. Its INSPIRA ART system employs advanced principles of extracorporeal oxygenation, substituting the direct mechanical intervention of traditional ventilators with a sophisticated intravascular apparatus. This device promises to stabilize oxygen levels rapidly without the complications that are often associated with mechanical ventilation, thereby offering patients the possibility of remaining awake during treatment.

Complementing the INSPIRA ART is the company’s innovative HYLA blood sensor technology. This AI-powered continuous monitoring system provides real-time data on a patient’s blood oxygenation and carbon dioxide levels, allowing healthcare professionals immediate access to critical parameters. The integration of HYLA enhances the utility of the INSPIRA ART, offering continuous feedback and contributing to a more informed clinical decision-making process.

Market Significance and Competitive Position

Inspira Technologies operates in a competitive yet rapidly evolving segment of the medical devices market. The problems associated with invasive mechanical ventilation, such as high treatment costs, complications, and a heavy burden on ICU resources, position the company’s offerings as potentially disruptive in a market that handles millions of cases of acute respiratory failure annually. By addressing both the mechanical and monitoring aspects of respiratory support through its dual technologies, the company is carving out a unique position that resonates with healthcare providers who seek safer, more efficient, and patient-centric solutions.

Regulatory Achievements and Clinical Insights

The company has achieved significant regulatory milestones, obtaining clearance for its INSPIRA ART systems in key procedures such as Cardiopulmonary Bypass. These clearances underscore the robustness and safety of its design. Additionally, the clinical evaluations of its HYLA blood sensor technology at internationally recognized medical institutions demonstrate the company’s commitment to aligning innovation with established clinical protocols and standards.

Product Portfolio and Operational Excellence

Beyond its flagship INSPIRA ART system and the supporting HYLA sensor, Inspira Technologies is actively developing a robust pipeline of products aimed at addressing various facets of respiratory support and blood monitoring. The company’s research, development, manufacturing, and marketing operations are tailored to meet the rigorous demands of modern critical care, emphasizing ease of use, rapid response, and integration with existing hospital systems.

Strategic Collaborations and Global Reach

Recognizing the global need for improved respiratory care, Inspira Technologies has engaged in strategic collaborations with leading hospitals and distributors across multiple regions including North America, Europe, and Asia Pacific. These partnerships not only validate the technological merits of the company’s products but also help penetrate diverse healthcare markets that continue to rely heavily on traditional ventilation methods.

Commitment to Quality and Clinical Impact

The company’s approach blends robust technological innovation with a keen understanding of clinical challenges. By focusing on continuous innovation through rigorous trial evaluations, adherence to regulatory standards, and integration of AI-powered analytics, Inspira Technologies is dedicated to enhancing patient outcomes in critical care settings while alleviating operational burdens on healthcare providers.

Conclusion

Inspira Technologies Oxy BHN Ltd represents a thoughtful blend of technical innovation and clinical pragmatism. It stands out for its effort to revolutionize respiratory support through cutting-edge non-invasive technologies that offer an alternative to conventional mechanical ventilation. With a comprehensive business model centered on enhancing both patient care and operational efficiency in critical care environments, the company is well-positioned in its sector as healthcare institutions increasingly seek solutions that combine safety, rapid responsiveness, and sustained reliability.

Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) has announced new support features for its FDA-cleared INSPIRA™ ART100 system, enhancing medical team procedures and efficiency in extracorporeal life support technology. The updates include integration with hospital procedures, system-activated alarm troubleshooting, and advanced software display features for complex care situations.

The ART100 system adds oxygen to blood and removes carbon dioxide, functioning as a heart-lung support for critical care patients. Key features include a compact design, four-hour emergency uptime, and compatibility with various disposable equipment. The system received FDA 510(k) clearance for CBP procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in May and July 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
-
Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) has delivered its INSPIRA™ ART100 systems to Glo-Med Networks for deployment at a leading U.S. hospital. The systems will be distributed to hospitals on the U.S. east coast, including a top-ranking cardiothoracic surgery division in New York.

The INSPIRA™ ART100, which received FDA 510(k) clearance for cardiopulmonary bypass procedures in May 2024, will be integrated with the HYLA™ blood monitoring technology. The HYLA™ is currently undergoing clinical evaluations at Sheba Hospital in preparation for FDA submission in 2025.

The company is developing breakthrough respiratory support technologies, including the INSPIRA ART, aimed at potentially replacing the $19 billion mechanical ventilation market. This technology is designed to stabilize decreasing oxygen levels without requiring ventilation, allowing patients to remain awake during treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) has appointed Tal Parnes as the new chairman of the board, effective February 1, 2025. Parnes, who has served as an independent director since July 2021, brings over 30 years of experience in technology, particularly in medical technology and pharmaceuticals. He succeeds Prof. Benad Goldwasser, who resigned for personal reasons.

Parnes' background includes co-founding and serving as CEO of Zuta-Core and HQL Pharmaceuticals , along with executive roles at several technology companies. The appointment aims to enhance Inspira's leadership and market position.

The company recently achieved significant milestones with its INSPIRA ART100 system receiving FDA 510(k) clearance for CBP procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in June and July 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
management
Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) has partnered with Zriha Medical to establish a dedicated production line for a important flow mechanism component of its respiratory support system. Zriha Medical, with over 50 years of experience and ISO 13485 certification, will manufacture components for extracorporeal blood circulation during oxygenation.

The company's flagship product, the INSPIRA ART, aims to revolutionize the $19 billion mechanical ventilation market by providing an alternative to traditional ventilators. The system recently received FDA 510(k) clearance for CBP procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in May and July 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Inspira Technologies has unveiled a modular configuration for its VORTX blood oxygenation delivery technology, targeting the $19 billion mechanical ventilation market. The VORTX system, protected by 32 novel patent claims, is designed to maintain more natural blood flow compared to traditional fiber-based oxygenators.

The company's flagship INSPIRA ART system aims to stabilize declining oxygen saturation levels in awake patients without requiring a ventilator, potentially benefiting approximately 20 million ICU patients with respiratory failure annually. In mid-2024, the INSPIRA ART100 system received both FDA 510(k) clearance for CBP procedures and Israeli AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The modular VORTX configuration is expected to extend the INSPIRA ART's capabilities in blood oxygen enrichment and carbon dioxide removal, enhancing its versatility across various medical scenarios.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) announced preparations for potential production ramp-up of its INSPIRA™ ART100 device in response to the human metapneumovirus (hMPV) outbreak in China. The company is engaging with leading providers in affected regions and securing raw materials to meet possible demand increases.

The INSPIRA ART100 device, which received FDA 510(k) clearance and Israeli AMAR certification in June and July 2024 for CBP procedures, offers an alternative to traditional mechanical ventilators. The technology aims to stabilize decreasing oxygen saturation levels without requiring ventilation, while patients remain awake during treatment.

The company's innovative system targets the $19 billion mechanical ventilation market, addressing the needs of 20 million ICU patients with acute respiratory failure annually. The device includes a HYLA™ blood sensor for real-time continuous monitoring without requiring blood samples.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) has announced its participation in the Arab Health 2025 exhibition, where it will showcase its FDA-cleared INSPIRA™ ART100 cardiopulmonary bypass system. The event, scheduled for January 27-30, 2025, at the Dubai World Trade Center, is expected to attract over 3,800 exhibitors from more than 180 countries.

The INSPIRA ART100 system is designed to oxygenate blood and remove carbon dioxide, effectively taking over heart and lung functions in critical care patients. The system features proprietary software for setup guidance, advanced customization options, and built-in alarm management with troubleshooting solutions. It offers up to four hours of emergency uptime, maintains a small footprint, and is compatible with various market-available disposables.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) has announced a $3.2M private placement offering, consisting of 4,608,715 ordinary shares (or pre-funded warrants) and warrants to purchase up to 4,608,715 ordinary shares at $0.70 per combined unit. The ordinary warrants have an eighteen-month term with a $1.10 exercise price.

The company, which develops respiratory support technology, plans to use the proceeds for working capital and general corporate purposes. The placement is expected to close around December 30, 2024, with Dawson James Securities acting as the exclusive placement agent.

Inspira's flagship product, the INSPIRA ART, has received FDA 510(k) clearance for Cardiopulmonary Bypass procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
private placement
-
Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) has delivered its INSPIRA™ ART100 systems to U.S. distributor Glo-Med Networks for deployment in east coast hospitals, including a leading New York cardiothoracic surgery division ranked in the top 15% nationally. The ART100, designed with U.S. clinicians, is FDA 510(k) cleared for Cardiopulmonary Bypass procedures and will be integrated with the HYLA™ blood monitoring technology, currently under clinical evaluation at Sheba Hospital.

The HYLA™ system is preparing for FDA submission in 2025, aiming to provide real-time patient condition monitoring without requiring blood samples. The company's broader technology portfolio includes the INSPIRA ART500, Cardi-ART portable device, and VORTX system, all still in development and pending regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
none
Rhea-AI Summary

Inspira Technologies (NASDAQ: IINN) announced the expansion of its HYLA blood sensor technology into personalized Blood Lab Testing. The technology aims to provide real-time patient blood work for rapid detection of life-threatening conditions within minutes, potentially replacing traditional blood sampling methods in extracorporeal procedures.

The HYLA system is designed for use in ERs, ICUs, Medical Units, and operating rooms, with potential benefits including replacement of expensive equipment, elimination of blood cartridges, reduced dependency on central labs, and decreased hospital staff burden. The technology is currently undergoing clinical evaluations at Sheba Hospital in patients undergoing open-heart procedures, with FDA submission planned for 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none

FAQ

What is the current stock price of Inspira Technologies Oxy Bhn (IINN)?

The current stock price of Inspira Technologies Oxy Bhn (IINN) is $0.686 as of March 28, 2025.

What is the market cap of Inspira Technologies Oxy Bhn (IINN)?

The market cap of Inspira Technologies Oxy Bhn (IINN) is approximately 18.5M.

What is the core business of Inspira Technologies Oxy BHN Ltd?

Inspira Technologies focuses on developing innovative respiratory support and life support technologies that serve as alternatives to invasive mechanical ventilation.

How does the INSPIRA ART system differ from traditional mechanical ventilators?

The INSPIRA ART system is designed to enhance oxygen levels and remove carbon dioxide using an intravascular approach, potentially reducing complications and allowing patients to remain awake during treatment.

What role does the HYLA blood sensor technology play in Inspira's product portfolio?

The HYLA blood sensor provides real-time, continuous monitoring of blood parameters, enabling immediate clinical feedback and supporting informed decisions during respiratory treatment.

Which market segments does Inspira Technologies serve?

The company targets the respiratory care and life support markets globally, with applications in intensive care units, operating rooms, and other critical care settings.

What regulatory achievements has Inspira Technologies accomplished?

Inspira Technologies has obtained key regulatory clearances, such as FDA 510(k) clearance for its INSPIRA ART systems in procedures like Cardiopulmonary Bypass, underscoring its commitment to safety and clinical efficacy.

How do Inspira Technologies' solutions benefit healthcare providers?

By offering non-invasive respiratory support and continuous blood monitoring, the company’s technologies can improve patient care, reduce the complications associated with traditional ventilation, and provide rapid clinical information.

What distinguishes Inspira Technologies within the competitive medical device market?

The company combines breakthrough respiratory support technology with advanced, AI-powered blood monitoring, positioning it uniquely against traditional ventilation methods and addressing key clinical challenges.
Inspira Technologies Oxy Bhn Ltd

Nasdaq:IINN

IINN Rankings

IINN Stock Data

18.46M
24.59M
4.01%
4.55%
0.61%
Medical Devices
Healthcare
Link
Israel
Ra'anana